Manufacturing Lilly inflates US facility investment spending by $4.5bn PharmaphorumHaving already committed last year to capital investments of $27 billion in the US to ward off the threat of tariffs, Eli Lilly has upped the ante.Read full story pharminent May 6, 2026 (Last updated: May 7, 2026) Pharmaphorum Having already committed last year to capital investments of $27 billion in the US to ward off the threat of tariffs, Eli Lilly has upped the ante. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: FDA Launches One-Day Inspectional Assessments to Strengthen and Expand OversightNext: Bayer looks to uphold Eylea legacy with $2.45bn Perfuse buyout Related Stories Manufacturing FDA Warning Letter Hits Sanofi’s Genzyme Ireland Site pharminent July 8, 2026 Manufacturing Tanabe pens deal to sell plants to Towa in post-buyout pivot pharminent July 8, 2026 Manufacturing FDA Selects Seven for PreCheck Pilot to Advance Drug Manufacturing pharminent July 1, 2026
